Pharmacoeconomic Evaluation of Costs of Myelomeningocele and Meningocele Treatment and Screening

• Published in: ClinicoEconomics and outcomes research 2024-01, Vol.16, p.69-80
• Main Authors: Hoxha, Malvina, Malaj, Visar, Zappacosta, Bruno, Firza, Najada
• Format: Article
• Language: English
• Subjects: cost; Cost benefit analysis; Medical care, Cost of; meningocele; Myelomeningocele; neural tube defects; pharmacoeconomic; Pregnant women; Review
• ISSN: 1178-6981; 1178-6981
• DOI: 10.2147/CEOR.S443120

The prevention of myelomeningocele (MMC) and meningocele (MC) is a public health concern. A systematic review on economic factors associated with MMC and MC can help the policy makers to evaluate the cost-effectiveness of screening and treatment. To our knowledge, this is the first systematic review to provide up-to date pharmacoeconomic evidence of all economic studies present in literature on different aspects of MMC and MC. We searched in the National Health Service Economic Evaluation Database (NHSEED), PubMed, Cost-effectiveness Analysis Registry (CEA Registry), Centre for Reviews and Dissemination (CRD), Health Technology Assessment Database (HTAD), Cochrane Library, and Econlit. The PRISMA guidelines were followed in the search and evaluation of literature. Only articles in English not limited by the year of publication that fulfilled the eligibility criteria were included in this systematic review. Nineteen papers were included in the study. The studies were very heterogeneous and reported a comparison of the costs between prenatal versus postnatal repair, the cost of fetoscopic approach versus open surgery, the cost of ventriculoperitoneal shunting (VPS) versus endoscopic third ventriculostomy (ETV), and ETV with choroid plexus cauterization (ETV/CPC), the cost of hospitalization, and the cost of diagnosis for MMC. The results of this study can help in implementing new policies in different countries to assist MC and MMC patients with the cost of treatment and screening.